Diligence memo · auto-generated · as of July 2, 2026

Regado Biosciences Inc

Regado Biosciences Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Regado Biosciences Inc operates in Biotechnology, based in BASKING RIDGE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Regado Biosciences Inc has raised $142M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $40M on 2010-03-30.

Most recent recorded round closed around 2014-02-05.

Valuation (modeled)modeled

Provath models Regado Biosciences Inc at approximately $794M (range $40M–$3.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.11× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era. Within the normal band (111% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 8 months.

Last raise 12.4 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.1× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 94% of Biotechnology peers (4293 compared).

Modeled value ranks above 87% of those peers.

Closest niche peers: BioAtla,LLC, Scholar Rock LLC, Oligasis, LLC, Alector LLC, Gelesis Inc.

Peoplefiled

15 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.